Get the Stockscreener App
5.32
2.21%
-0.12
Karyopharm Therapeutics Inc stock is traded at $5.32, with a volume of 35,974.
It is down -2.21% in the last 24 hours and up +20.36% over the past month.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
See More
Previous Close:
$5.44
Open:
$5.5
24h Volume:
35,974
Relative Volume:
0.29
Market Cap:
$45.96M
Revenue:
$140.46M
Net Income/Loss:
$-146.34M
P/E Ratio:
-4.189
EPS:
-1.27
Net Cash Flow:
$-117.73M
1W Performance:
-11.48%
1M Performance:
+20.36%
6M Performance:
-56.43%
1Y Performance:
-68.75%
1-Day Range:
$5.2473
$5.6396
1-Week Range:
$4.64
$6.2248
52-Week Range:
$3.51
$17.85
Karyopharm Therapeutics Inc Stock (KPTI) Company Profile
Name
Karyopharm Therapeutics Inc
Sector
Industry
Phone
617-658-0600
Address
85 WELLS AVENUE, NEWTON, MA
Compare KPTI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KPTI
Karyopharm Therapeutics Inc
|
5.32 | 51.51M | 140.46M | -146.34M | -117.73M | -1.27 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Karyopharm Therapeutics Inc Stock (KPTI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-19-23 | Initiated | Piper Sandler | Overweight |
| Nov-04-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-09-22 | Upgrade | JP Morgan | Underweight → Neutral |
| Nov-19-21 | Resumed | Morgan Stanley | Equal-Weight |
| Aug-06-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-06-21 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-06-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-02-20 | Initiated | Morgan Stanley | Overweight |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-17-20 | Downgrade | Wedbush | Outperform → Neutral |
| Jul-23-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-05-19 | Reiterated | H.C. Wainwright | Buy |
| Jul-05-19 | Reiterated | Robert W. Baird | Outperform |
| Mar-01-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-28-19 | Reiterated | BofA/Merrill | Underperform |
| Feb-27-19 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Jan-03-19 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Dec-03-18 | Initiated | B. Riley FBR | Buy |
| Nov-09-18 | Upgrade | Wedbush | Neutral → Outperform |
| May-24-18 | Downgrade | Wedbush | Outperform → Neutral |
| Apr-02-18 | Resumed | Leerink Partners | Outperform |
| Nov-15-17 | Resumed | H.C. Wainwright | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Sep-08-16 | Reiterated | H.C. Wainwright | Buy |
| Aug-30-16 | Upgrade | Jefferies | Hold → Buy |
| Aug-18-16 | Initiated | H.C. Wainwright | Buy |
| Jun-28-16 | Initiated | Robert W. Baird | Outperform |
View All
Karyopharm Therapeutics Inc Stock (KPTI) Latest News
StockNews.com Downgrades Karyopharm Therapeutics (NASDAQ:KPTI) to Sell - Defense World
Leerink Partnrs Issues Positive Estimate for KPTI Earnings - Defense World
Brokerages Set Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Price Target at $45.60 - Defense World
Karyopharm targets $1B peak U.S. revenue in myelofibrosis as Phase 3 SENTRY enrollment nears completion - MSN
Karyopharm’s Earnings Call: Clinical Gains Amid Financial Strains - TipRanks
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q1 2025 Earnings Call Transcript - Insider Monkey
Robert W. Baird Issues Pessimistic Forecast for Karyopharm Therapeutics (NASDAQ:KPTI) Stock Price - Defense World
Karyopharm Announces Poster Presentation on Selinexor in Myelofi - GuruFocus
KPTI to Present Promising Selinexor Data at Upcoming Hematology Meeting | KPTI Stock News - GuruFocus
Karyopharm abstract selected for presentation at 2025 EHA meeting - TipRanks
Karyopharm Announces Poster Presentation on Selinexor in Myelofibrosis at the 2025 European Hematology Association Annual Meeting - PR Newswire
KPTI: RBC Capital Lowers Price Target while Maintaining Outperfo - GuruFocus
RBC Capital cuts Karyopharm stock price target to $33 By Investing.com - Investing.com Canada
These Analysts Revise Their Forecasts On Karyopharm Therapeutics After Q1 Results - Benzinga
KPTI Misses Q1 Revenue Estimates but Advances Myelofibrosis Tria - GuruFocus
KPTI Stock Boosted as Barclays Raises Price Target to $10 | KPTI - GuruFocus
Karyopharm (KPTI) Target Price Reduced by RBC Capital | KPTI Sto - GuruFocus
KPTI: Baird Lowers Price Target but Maintains Outperform Rating - GuruFocus
Karyopharm (KPTI) Price Target Reduced by Baird, Outperform Rati - GuruFocus
Karyopharm Therapeutics Inc Reports Q1 2025 Earnings: EPS Loss o - GuruFocus
RBC Adjusts Price Target on Karyopharm Therapeutics to $33 From $43, Maintains Outperform Rating - marketscreener.com
Barclays Updates Karyopharm (KPTI) Price Target, Eyes Future Dat - GuruFocus
Karyopharm Therapeutics Inc (KPTI) Q1 2025 Earnings Call Highlights: Promising Clinical ... - Yahoo Finance
Karyopharm Therapeutics Inc (KPTI) Q1 2025 Earnings Call Highlig - GuruFocus
Karyopharm Q1 2025 slides: Myelofibrosis opportunity takes center stage By Investing.com - Investing.com Canada
Karyopharm Therapeutics Reports Q1 2025 Earnings and Clinical Progress - TipRanks
Earnings call transcript: Karyopharm Q1 2025 shows mixed market reaction By Investing.com - Investing.com Nigeria
Karyopharm Reports First Quarter 2025 Financial Results and Announces New Data in Myelofibrosis that Further Suggests Selinexor May Lead to Meaningful Spleen Volume Reduction, Symptom Improvement, Hemoglobin Stabilization and Disease Modificati - Citizen Tribune
Earnings call transcript: Karyopharm Q1 2025 shows mixed market reaction - Investing.com
KPTI Projects Funding into Early 2026 Supported by XPOVIO Sales - GuruFocus
Karyopharm Reports First Quarter 2025 Financial Results and Anno - GuruFocus
Karyopharm Therapeutics: Q1 Earnings Snapshot - San Antonio Express-News
Karyopharm Therapeutics (KPTI) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Karyopharm Q1 2025 slides: Myelofibrosis opportunity takes center stage - Investing.com
Karyopharm Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Karyopharm Therapeutics Inc. SEC 10-Q Report - TradingView
Karyopharm Therapeutics Q1 2025 Earnings Call Transcript - MarketBeat
Karyopharm to Report First Quarter 2025 Financial Results on May 12, 2025 - Eastern Progress
Investor Network: Karyopharm Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Karyopharm to Report First Quarter 2025 Financial Results on May 12, 2025 | KPTI Stock News - GuruFocus
Redefining Myelofibrosis Care: Can Karyopharm's Selinexor Lead The Way? - RTTNews
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Citizen Tribune
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq L - GuruFocus
Karyopharm Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Karyopharm Therapeutics (NASDAQ:KPTI) Shares Cross Below 200-Day Moving Average – Here’s Why - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Medidata Solutions, Inc. Announces Expanded Partnership with Karyopharm Therapeutics - marketscreener.com
Triple Refractory Multiple Myeloma Therapeutics Market Size - openPR.com
Trial misses sink cancer stocks in Q1: Mersana, Cargo, Mural fall - BioWorld MedTech
Karyopharm Therapeutics Inc Stock (KPTI) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.54%
7.58%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):